Clyde & Co’s cases in Biotech & Life Sciences

Member firm: Clyde & Co. LLP
  • Advising on investor participation in early and later stage funding rounds.

  • Advising early stage companies on UK set up issues such as grant funding, employment, tax structuring and real estate.

  • Advising a biotech company on heads of agreement for strategic collaborations with pharma companies on a biomarker platform for the diagnosis of diseases associated with aberrant gene expression and new sports drink.

  • Advising Shire Pharmaceuticals Group on employment aspects of its $200 million disposal of a pan-European pharmaceuticals business.

  • Patent and contractual due diligence exercises for a UK mid-sized pharma company relating to its proposed acquisitions and licensing-in of medicines.

  • Advising a biotech company on the research exemptions to patent infringement and their application to the use of RNAi libraries for elucidating the modes of action of new drugs.

  • Advising a generic pharmaceutical company on the validity of a patent protecting a blockbuster drug and on a litigation strategy in the English courts.

  • Acting for TDL Genetics in defence of a patent infringement action concerning a non-invasive pre-natal genetic test for foetal aneuploidies such as Down’s syndrome.

  • Acting in a highly complex international commercial arbitration against a multinational medical devices, pharmaceutical and consumer packaged goods manufacturer.

  • Defending Cardinal Health in an arbitration under the CIETAC rules in Beijing in relation to a claim for breach of confidentiality arising from an alleged misuse of technology.

  • Representing a diet clinic in UK copyright and trade mark infringement and passing off proceedings relating to a weight loss therapy and food and treatment plans.

  • Representing insurer for a private hospital group in claims by patients given breast implants filled with non-medical-grade silicone.